 |
|
 |
专题栏目 |
 |
|
相关文章 |
|
|
|
|
|
 |
β2受体激动剂治疗COPD效果肯定 |
热 荐 ★★★ |
|
| β2受体激动剂治疗COPD效果肯定 |
|
作者：盖科医疗 文章来源：http://www.copd.com.cn 点击数： 更新时间：2007-5-8 17:03:45  |
|
英国Ram等的一项荟萃分析结果肯定了吸入性短效β 2 受体激动剂治疗稳定性慢性阻塞性肺病（COPD）的疗效。
Ram等荟萃分析了13项随机、对照的临床试验，共包括了237例稳定性COPD患者。这些患者都接受了7天～8周的吸入性短效β2受体激动剂（如沙丁胺醇、特布他林）治疗，其临床症状和肺功能都得到了显著改善。Ram认为，这类价格低廉的老药与噻托溴铵和氟替卡松等较为昂贵的新药相比，治疗效果有过之而无不及，应作为COPD患者治疗时的首选药物。
Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.
Ram FS, Sestini P.
St George's Hospital Medical School, Department of Physiological Medicine, University of London, UK. fram@sghms.ac.uk
BACKGROUND: Despite the lack of reversibility, patients with chronic obstructive pulmonary disease (COPD) often report symptomatic improvement with inhaled short acting beta(2) agonist bronchodilators (ISABAs) in the management of both stable and acute exacerbations of COPD. A review of the literature was undertaken to determine the effectiveness of regular treatment with ISABAs compared with placebo in stable COPD. METHODS: A search for randomised controlled trials was carried out using the Cochrane Collaboration database of trials up to and including May 2002. RESULTS: Thirteen studies of 7 days to 8 weeks in duration on 237 patients aged 56-70 years with forced expiratory volume in 1 second (FEV(1)) 60-70% predicted were included in the review. All studies used a crossover design with adequate washout periods and were of high methodological quality. ISABA was delivered either through a nebuliser or a pressurised metered dose inhaler. Spirometric tests performed at the end of the study and after the treatment (post-bronchodilator) showed a slight but significant increase in FEV(1) and forced vital capacity (FVC) compared with placebo. In addition, both morning and evening peak expiratory flow rate (PEFR) were significantly better during active treatment than during placebo. An improvement in the daily breathlessness score was observed with ISABA treatment. The risk of treatment failure was reduced by more than 50% with ISABA. Preference for ISABA was nine times higher than for placebo. CONCLUSIONS: Use of ISABA on a regular basis for at least 7 days in patients with stable COPD is associated with improvements in post-bronchodilator lung function and decreases in both breathlessness and treatment failure. This review has shown that regular administration of ISABAs is an effective and inexpensive treatment for the management of patients with stable COPD.
|
|
| 文章录入：kong 责任编辑：kong |
|
|
上一篇文章： COPD的临床表现和诊断
下一篇文章： COPD晚期反复发生严重呼衰机械通气治疗 |
|
|
| 【字体：小 大】【发表评论】【加入收藏】【告诉好友】【打印此文】【关闭窗口】 |
|
 网友评论：（只显示最新10条。评论内容只代表网友观点，与本站立场无关！） |
| |
|
|
|
|
